RU2010109452A - Способы и композиции, предназначенные для лечения раковых заболеваний - Google Patents
Способы и композиции, предназначенные для лечения раковых заболеваний Download PDFInfo
- Publication number
- RU2010109452A RU2010109452A RU2010109452/15A RU2010109452A RU2010109452A RU 2010109452 A RU2010109452 A RU 2010109452A RU 2010109452/15 A RU2010109452/15 A RU 2010109452/15A RU 2010109452 A RU2010109452 A RU 2010109452A RU 2010109452 A RU2010109452 A RU 2010109452A
- Authority
- RU
- Russia
- Prior art keywords
- agent
- abl
- bcr
- ability
- inhibit
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 13
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims abstract 16
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims abstract 8
- 241000289669 Erinaceus europaeus Species 0.000 claims abstract 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims abstract 4
- 239000003112 inhibitor Substances 0.000 claims abstract 4
- 208000032839 leukemia Diseases 0.000 claims abstract 4
- 230000037361 pathway Effects 0.000 claims abstract 4
- 230000008054 signal transmission Effects 0.000 claims abstract 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims abstract 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims abstract 2
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims abstract 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims abstract 2
- 229940118364 Bcr-Abl inhibitor Drugs 0.000 claims abstract 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims abstract 2
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 claims abstract 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims abstract 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims abstract 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims abstract 2
- 239000003719 aurora kinase inhibitor Substances 0.000 claims abstract 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims abstract 2
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 229940126601 medicinal product Drugs 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Композиция, содержащая первый агент, который обладает способностью ингибировать путь передачи сигнала hedgehog, и второй агент, который обладает способностью ингибировать BCR-ABL. ! 2. Композиция по п.1, в которой первый агент связывается с Smo. ! 3. Композиция по п.1, в которой первый агент представляет собой циклопамин или форсколин. ! 4. Композиция по п.1, в которой второй агент представляет собой ингибитор ABL, ингибитор ABL/Scr, ингибитор киназы Aurora или не-АТФ-конкурентный ингибитор BCR-ABL. ! 5. Композиция по п.1, в которой второй агент выбран из группы, включающей ! ! ! ! ! ! , , и . ! 6. Фармацевтическая композиция, содержащая в терапевтически эффективном количестве первый агент, который обладает способностью ингибировать путь передачи сигнала hedgehog, второй агент, который обладает способностью ингибировать BCR-ABL, и фармацевтически приемлемый носитель. ! 7. Применение композиции по одному из пп.1-6 для приготовления лекарственного средства, предназначенного для лечения BCR-ABL-позитивного лейкоза. ! 8. Применение по п.7, в котором BCR-ABL-позитивный лейкоз представляет собой хронический миелолейкоз или острый лимфолейкоз.
Claims (8)
1. Композиция, содержащая первый агент, который обладает способностью ингибировать путь передачи сигнала hedgehog, и второй агент, который обладает способностью ингибировать BCR-ABL.
2. Композиция по п.1, в которой первый агент связывается с Smo.
3. Композиция по п.1, в которой первый агент представляет собой циклопамин или форсколин.
4. Композиция по п.1, в которой второй агент представляет собой ингибитор ABL, ингибитор ABL/Scr, ингибитор киназы Aurora или не-АТФ-конкурентный ингибитор BCR-ABL.
5. Композиция по п.1, в которой второй агент выбран из группы, включающей
6. Фармацевтическая композиция, содержащая в терапевтически эффективном количестве первый агент, который обладает способностью ингибировать путь передачи сигнала hedgehog, второй агент, который обладает способностью ингибировать BCR-ABL, и фармацевтически приемлемый носитель.
7. Применение композиции по одному из пп.1-6 для приготовления лекарственного средства, предназначенного для лечения BCR-ABL-позитивного лейкоза.
8. Применение по п.7, в котором BCR-ABL-позитивный лейкоз представляет собой хронический миелолейкоз или острый лимфолейкоз.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95629507P | 2007-08-16 | 2007-08-16 | |
| US60/956,295 | 2007-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010109452A true RU2010109452A (ru) | 2011-09-27 |
Family
ID=40210407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010109452/15A RU2010109452A (ru) | 2007-08-16 | 2008-08-13 | Способы и композиции, предназначенные для лечения раковых заболеваний |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20100216828A1 (ru) |
| EP (1) | EP2187967B1 (ru) |
| JP (1) | JP2010536775A (ru) |
| KR (1) | KR20100056525A (ru) |
| CN (1) | CN101820915A (ru) |
| AU (1) | AU2008289255B2 (ru) |
| BR (1) | BRPI0815330A2 (ru) |
| CA (1) | CA2699988A1 (ru) |
| DK (1) | DK2187967T3 (ru) |
| ES (1) | ES2422285T3 (ru) |
| HR (1) | HRP20130642T1 (ru) |
| MX (1) | MX2010001813A (ru) |
| PL (1) | PL2187967T3 (ru) |
| RU (1) | RU2010109452A (ru) |
| SI (1) | SI2187967T1 (ru) |
| WO (1) | WO2009026075A1 (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110117212A1 (en) * | 2008-07-24 | 2011-05-19 | Nerviano Medical Sciences S.R.L. | Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent |
| US20110039850A1 (en) * | 2009-08-12 | 2011-02-17 | Mhairi Copland | Leukemia Treatment |
| RU2012120901A (ru) * | 2009-10-23 | 2013-12-10 | Новартис Аг | Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r |
| WO2013187967A1 (en) | 2012-06-15 | 2013-12-19 | Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") | Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control |
| CN103768067A (zh) * | 2012-10-23 | 2014-05-07 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN104262262B (zh) * | 2014-08-29 | 2016-06-08 | 西安交通大学 | 一种N,6二苯基嘧啶-4-胺类Bcr-Abl抑制剂及其制备方法和应用 |
| CN109744199A (zh) * | 2017-11-08 | 2019-05-14 | 南京艾莫瑞生物科技有限公司 | 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用 |
| WO2018211007A1 (en) * | 2017-05-18 | 2018-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of mast cell diseases |
| CN108721217B (zh) * | 2018-08-21 | 2020-09-08 | 武汉轻工大学 | 抗肿瘤药物组合物及药物制剂和应用 |
| US20200297725A1 (en) * | 2019-03-22 | 2020-09-24 | Yale University | Allosteric bcr-abl proteolysis targeting chimeric compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| US6291516B1 (en) | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
| ATE404200T1 (de) | 2002-04-22 | 2008-08-15 | Univ Johns Hopkins Med | Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| CN102964294A (zh) | 2004-09-02 | 2013-03-13 | 遗传技术研究公司 | Hedgehog信号转导的吡啶基抑制剂 |
| WO2006102611A2 (en) * | 2005-03-24 | 2006-09-28 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of leukemia |
-
2008
- 2008-08-13 PL PL08797814T patent/PL2187967T3/pl unknown
- 2008-08-13 CA CA2699988A patent/CA2699988A1/en not_active Abandoned
- 2008-08-13 BR BRPI0815330A patent/BRPI0815330A2/pt not_active IP Right Cessation
- 2008-08-13 MX MX2010001813A patent/MX2010001813A/es active IP Right Grant
- 2008-08-13 US US12/673,178 patent/US20100216828A1/en not_active Abandoned
- 2008-08-13 KR KR1020107005683A patent/KR20100056525A/ko not_active Application Discontinuation
- 2008-08-13 ES ES08797814T patent/ES2422285T3/es active Active
- 2008-08-13 RU RU2010109452/15A patent/RU2010109452A/ru not_active Application Discontinuation
- 2008-08-13 CN CN200880102489A patent/CN101820915A/zh active Pending
- 2008-08-13 JP JP2010521142A patent/JP2010536775A/ja active Pending
- 2008-08-13 AU AU2008289255A patent/AU2008289255B2/en not_active Ceased
- 2008-08-13 WO PCT/US2008/073049 patent/WO2009026075A1/en active Application Filing
- 2008-08-13 DK DK08797814.4T patent/DK2187967T3/da active
- 2008-08-13 SI SI200830983T patent/SI2187967T1/sl unknown
- 2008-08-13 EP EP08797814.4A patent/EP2187967B1/en not_active Not-in-force
-
2012
- 2012-03-05 US US13/411,963 patent/US20120165355A1/en not_active Abandoned
-
2013
- 2013-02-13 US US13/765,713 patent/US20130210771A1/en not_active Abandoned
- 2013-07-08 HR HRP20130642AT patent/HRP20130642T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2699988A1 (en) | 2009-02-26 |
| CN101820915A (zh) | 2010-09-01 |
| SI2187967T1 (sl) | 2013-07-31 |
| US20100216828A1 (en) | 2010-08-26 |
| AU2008289255B2 (en) | 2012-02-02 |
| EP2187967B1 (en) | 2013-04-24 |
| BRPI0815330A2 (pt) | 2017-05-09 |
| US20130210771A1 (en) | 2013-08-15 |
| PL2187967T3 (pl) | 2013-09-30 |
| ES2422285T3 (es) | 2013-09-10 |
| AU2008289255A1 (en) | 2009-02-26 |
| KR20100056525A (ko) | 2010-05-27 |
| DK2187967T3 (da) | 2013-07-22 |
| EP2187967A1 (en) | 2010-05-26 |
| US20120165355A1 (en) | 2012-06-28 |
| MX2010001813A (es) | 2010-03-10 |
| WO2009026075A1 (en) | 2009-02-26 |
| JP2010536775A (ja) | 2010-12-02 |
| HRP20130642T1 (en) | 2013-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010109452A (ru) | Способы и композиции, предназначенные для лечения раковых заболеваний | |
| NL300889I2 (nl) | Trifluridine in combinatie met tipiracilhydrochloride | |
| BRPI0507497A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, e, métodos para prevenir e/ou tratar distúrbios mediados por receptor de mglur5 e para inibir a ativação de receptores de mglur5 | |
| TW200610531A (en) | Phthalazine derivatives as PARP inhibitors | |
| TW200612950A (en) | Quinazolinedione derivatives as PARP inhibitors | |
| RS52956B (en) | CANCER TREATMENT COMPOSITIONS | |
| TNSN06439A1 (fr) | Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique | |
| BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
| CY1112828T1 (el) | Ενωσεις αναστολης της μιτωτικης διαδικασιας | |
| WO2007095124A3 (en) | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | |
| IS2855B (is) | 4-anilínókínasólínafleiður sem andfjölgunarefni | |
| NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
| MXPA05008368A (es) | 1,2,4-triazinas inhibidoras del virus de inmunodeficiencia humana. | |
| AR045161A1 (es) | Derivados de quinazolina | |
| AR058085A1 (es) | Sal de dihidrogeno fosfato de un antagonista del receptor de prostaglandina d2. composiciones farmaceuticas. | |
| SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
| ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
| CL2007000918A1 (es) | Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica. | |
| FR2869540B1 (fr) | Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers | |
| MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| ECSP099767A (es) | Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas | |
| MY154591A (en) | Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor | |
| BRPI0816798A2 (pt) | composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação | |
| CR6824A (es) | Derivados de arilmetilamina para uso como inhibidores de triptasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130905 |